At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 143 enrolled
Drug / intervention
CT-P6 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Parallel Phase I/IIb Study to Evaluate Initial Safety and Efficacy, Comparative Pharmacokinetics, and Immunogenicity for CT-P6 and Herceptin in Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating CT-P6, Herceptin, and 1 other intervention for Metastatic Breast Cancer. Completed, enrolled 143 participants across 1 site.
Detailed Summary
The purpose of the study is to demonstrate equivalent pharmacokinetics (PK)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesSouth Korea
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedMar 2010
Primary CompletionDec 2011
Study CompletionDec 2023
TodayJul 2026
First PostedMar 11, 2010
Enrollment StartFeb 1, 2010
Primary CompletionDec 1, 2011
Study CompletionDec 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.3 years ago
Interventions
CT-P6drug
CT-P6: administered every 3 weeks
Herceptindrug
Herceptin: administered every 3 weeks
Paclitaxeldrug
Paclitaxel: administered every 3 weeks